Q-omics provides the consensus-scored C2CD6 profile across patient tissues and cancer cell-line models. C2CD6 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, C2CD6 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, C2CD6 RNA expression shows 18,514 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KICH, and UVM as cancer lineages where C2CD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2CD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2CD6 survival associations across molecular data types. C2CD6 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2CD6 RNA expression–survival associations across cancer types. High C2CD6 expression shows unfavorable associations in UCEC, UVM, KIRC and BLCA, but favorable associations in LUAD and HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for C2CD6 RNA expression.
This table summarizes C2CD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for C2CD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2CD6 shows lower tumor expression in KICH and BRCA and higher tumor expression in LUAD, LUSC, HNSC and CHOL. The KICH box plot shows higher C2CD6 RNA expression in normal versus tumor tissue (log2 FC = −0.287, t-test p < 0.001).
This table shows molecular features associated with C2CD6 in patient tissues and cancer cell lines. In patient samples, C2CD6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C2CD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
